丝光绿蝇幼虫唾液和血液对治疗 BALB/c 小鼠大内脏利什曼原虫病变的疗效946.

The therapeutic effect of larval saliva and hemolymph of Lucilia sericata on the treatment of Leishmania major lesion in BALB/c mice946.

机构信息

Medicinal Plants Research Center, Maragheh University of Medical Sciences, Maragheh, Iran.

Department of Medical Entomology and Vector Control, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Parasit Vectors. 2023 Feb 16;16(1):72. doi: 10.1186/s13071-023-05660-0.

DOI:10.1186/s13071-023-05660-0

PMID:36797798

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9936726/

Abstract

BACKGROUND

Treatment of cutaneous leishmaniasis (CL) remains a major challenge for the public health and medical community. It has been claimed that natural compounds derived from fly larvae have anti-leishmania properties against some species of Leishmania. The present study aimed at assessing the in vitro effects of larval products of Lucilia sericata against the promastigote and intracellular amastigote forms of Leishmania major. Also, the therapeutic effect of larval products on lesions induced by L. major infection was evaluated in BALB/c mice models.

METHODS

Parasite specimens and macrophage cells were exposed to varying concentrations of larval products for 24-120 h. Lesion progression and parasite load were investigated in the models to assess the therapeutic effects of the products.

RESULTS

The larval products displayed more potent cytotoxicity against L. major promastigotes. The IC values for larval saliva and hemolymph were 100.6 and 37.96 ug/ml, respectively. The IC of glucantime was 9.480 ug/ml. Also, the saliva and hemolymph of L. sericata exhibited higher cytotoxicity against the promastigotes of L. major but were less toxic to the macrophage cells. Treatment with leishmanicidal agents derived from larvae of L. sericata decreased the infection rate and the number of amastigotes per infected host cell at all concentrations. Lesion size was significantly (F = 8.54, P < 0.0001) smaller in the treated mice compared with the untreated control group. The average parasite burden in the treated mice groups (1.81 ± 0.74, 1.03 ± 0.45 and 3.37 ± 0.41) was similar to the group treated with a daily injection of glucantime (1.77 ± 0.99) and significantly lower (F = 66.39, P < 0.0001) than in the untreated control group (6.72 ± 2.37).

CONCLUSIONS

The results suggest that the larval products of L. sericata were effective against L. major parasites both in vivo and in vitro. However, more clinical trial studies are recommended to evaluate the effects of these larval products on human subjects.

摘要

背景

皮肤利什曼病（CL）的治疗仍然是公共卫生和医学界面临的主要挑战。有人声称，源自蝇幼虫的天然化合物对某些利什曼原虫物种具有抗利什曼原虫特性。本研究旨在评估丝光绿蝇幼虫产品对利什曼原虫大滋养体和细胞内无鞭毛体形式的体外影响。此外，还在 BALB/c 小鼠模型中评估了幼虫产品对 L. major 感染引起的病变的治疗效果。

方法

将寄生虫标本和巨噬细胞暴露于不同浓度的幼虫产品中 24-120 小时。在模型中研究病变进展和寄生虫负荷以评估产品的治疗效果。

结果

幼虫产品对 L. major 前鞭毛体显示出更强的细胞毒性。幼虫唾液和血淋巴的 IC 值分别为 100.6 和 37.96 ug/ml，而葡萄糖胺的 IC 值为 9.480 ug/ml。此外，丝光绿蝇的唾液和血淋巴对 L. major 的前鞭毛体表现出更高的细胞毒性，但对巨噬细胞的毒性较低。用源自丝光绿蝇幼虫的杀利什曼原虫剂治疗可降低所有浓度下的感染率和每个感染宿主细胞的无鞭毛体数量。与未治疗的对照组相比，治疗组的病变大小明显（F=8.54，P<0.0001）更小。治疗组的平均寄生虫负担（1.81±0.74、1.03±0.45 和 3.37±0.41）与每天注射葡萄糖胺（1.77±0.99）的组相似，且显著低于（F=66.39，P<0.0001）未治疗的对照组（6.72±2.37）。